Inhibition of human pancreatic cancer by β2-adrenergic antagonist via suppression of invasion

Jun XU,Wei-jing MU,Huan-chen SHA,Zheng WANG,Dong ZHANG,Qing-yong MA

DOI: https://doi.org/10.3969/j.issn.1671-8259.2012.05.005

2012-01-01

Abstract:Objective: To study the effect of β 2 adrenergic antagonist on the proliferation and invasiveness of pancreatic cancer cell line and its action mechanism. Methods: The cancer cell proliferation was determined by MTT assay; the cancer cell invasion was detected by transwell assay; the cell cycle distribution was determined by the flow cytometry assay; the activation of NF-κB and AP-1 was measured by electrophoretic mobility shift assays; and the protein expression of VEGF, COX-2, MMP-2 and MMP-9 was analyzed by Western blot. Results: β 2-adrenergic antagonist ICI118551 and β 1/2-adrenergic antagonist propranolol significantly induced G 1/S phase arrest and apoptosis and suppressed cell invasion and proliferation as compared to β 1-adrenergic antagonist metoprolol and control. In our study, β 2-adrenoceptor antagonists inhibited activation of transcription factors NF-κB and AP-1. Moreover, β 2-adrenoceptor antagonist therapy significantly altered VEGF, COX-2, MMP-2 and MMP-9 expressions. The effect of the ICI118, 551 was stronger in BxPC-3 cell line than in MIA PaCa-2 cell line. Conclusion: β 2-adrenergic antagonists could suppress invasion and proliferation by inhibiting activation of NF-κB and AP-1 as well as expression of its target genes, such as MMP-9, MMP-2, VEGF and COX-2.